ASMB
Assembly Biosciences, Inc.
ASMB has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ASMB overall, supported by stronger fundamentals and stronger modeled upside.
ASMB Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Unavailable |
ASMB's revenue is currently healthy, and its profitability is stable, but its cash flow is under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ASMB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $19.00 | -5.8% |
| Current | 20x | $20.18 | — |
| Fair | 124x | $124 | +513% |
| Expensive | 344x | $344 | +1604% |
Historical ranges are pointers, not guarantees.
ASMB's PE is 20x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ASMB in the historical PE scenario, which offers more potential upside but is not a forecast.
ASMB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect ASMB's losses to shrink, with revenue growing.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ASMB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $1.00 | +$5.76 |
| Q2 2026 | $1.21 | +$6.76 |
| Q1 2026 | $0.08 | +$6.28 |
| Q4 2025 | -$0.55 | +$6.14 |
| Q3 2025 | -$4.76 | +$2.25 |
| Q2 2025 | -$5.55 | +$3.19 |
| Q1 2025 | -$6.20 | +$4.40 |
| Q4 2024 | -$6.69 | +$6.69 |
ASMB has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ASMB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3M | -73% |
| Q2 2026 | $13.4M | +39% |
| Q1 2026 | $8.2M | -13% |
| Q4 2025 | $42.5M | +477% |
| Q3 2025 | $10.8M | +58% |
| Q2 2025 | $9.6M | +13% |
| Q1 2025 | $9.4M | +63% |
| Q3 2021 | $6.3M | -82% |
ASMB's revenue is growing: $3M last quarter, down 73% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -792% | -691 points |
| Q2 2026 | -47% | +68 points |
| Q1 2026 | -138% | -33 points |
| Q4 2025 | 47% | +203 points |
| Q3 2025 | -101% | +59 points |
| Q2 2025 | -115% | +28 points |
| Q1 2025 | -106% | +80 points |
| Q4 2024 | -157% | N/A |
ASMB's operating margin was −792% last quarter, down 691 points from the same quarter a year ago, near the bottom of its range since 2019.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ASMB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over ASMB on profitability, with a higher operating margin.
ASMB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$17.3M | -$2.1M |
| Q2 2026 | -$15.5M | +$1.3M |
| Q1 2026 | -$22.1M | +$1.3M |
| Q4 2025 | $14.2M | +$14.6M |
| Q3 2025 | -$15.2M | +$69K |
| Q2 2025 | -$16.8M | +$358K |
| Q1 2025 | -$23.4M | -$5.1M |
| Q4 2024 | -$407K | -101% |
ASMB has burned cash in almost every quarter: −$41M over the past year, against −$56M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ASMB on cash generation, producing positive trailing cash flow while its opponent burns cash.
ASMB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +16% | +2.9M shares |
| 1 year | +184% | +14.1M shares |
| 3 years | +400% | +17.4M shares |
| 5 years | +510% | +18.2M shares |
| Available history | +895% | +19.6M shares |
ASMB has 22M diluted shares, up 184% from a year ago.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over ASMB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ASMB Net Leverage
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
ASMB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 5.7 | Oversold |
ASMB's weekly RSI is 38 (neutral) and its Stochastic is 6 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ASMB PE vs Healthcare Sector
| Metric | ASMB | Sector median | Relative |
|---|---|---|---|
| PE | 20x | 26x | 22% below |
| PE % | 26 | 29 | 3 pts below |
ASMB is trading at 20x earnings, a 22% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ASMB on valuation relative to its sector.
ASMB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.3 | 5.3% below |
| 20 week MA | $26.1 | 23% below |
| 50 week MA | $27.8 | 27% below |
| 100 week MA | $23.4 | 14% below |
| 200 week MA | $18.4 | 9.9% above |
ASMB has fallen below most of its moving averages, though it's still 9.9% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over ASMB on trend strength, trading above more of its moving averages.
ASMB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $251.3 | $74.4 | -70% |
| 2021 | $74.4 | $27.2 | -63% |
| 2022 | $27.2 | $15.1 | -44% |
| 2023 | $15.1 | $9.84 | -35% |
| 2024 | $9.84 | $15.2 | +54% |
| 2025 | $15.2 | $33.6 | +122% |
| 2026 YTD | $33.6 | $20.2 | -40% |
ASMB's yearly returns have swung widely, from +122% in 2025 to −70% in 2020. It's down 40% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ASMB on returns for 2026, with the stronger performance.